Division of Cardiology, The Heart Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
Division of Pulmonology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
Heart. 2018 Feb;104(3):254-260. doi: 10.1136/heartjnl-2017-311764. Epub 2017 Aug 3.
To describe acute and mid-term outcomes following presentation with, and treatment for, life-threatening airway bleeding (hemoptysis) in palliated single ventricle congenital heart disease (SV-CHD).
Case series of patients with SV-CHD who presented to a large congenital heart centre with hemoptysis between 2004 and 2015.
Twenty-one episodes of hemoptysis occurred in 12 patients (58% female, median 10.5 (IQR 7.2, 16.4) years). First hemoptysis episode occurred after Fontan completion (n=8), after superior cavopulmonary anastomosis (SCPA, n=3) and in one shunt-dependent patient. Bronchoscopy was performed in conjunction with catheterisation in 14/21 (67%) initial catheterisations. A specific anatomic source of airway bleeding was identified in 95% of bronchoscopy cases and was uniformly distributed in all lobar segments. Transcatheter intervention with systemic-to-pulmonary collateral artery (SPC) occlusion was performed in 28/30 catheterisations. Apart from increased airway bleeding during interventional bronchoscopy (37%), there were no procedural complications. Median hospital length of stay was 9.0 (3.5, 14.5) days with patients undergoing 1.0 (1.0,2.0) catheterisations per episode of hemoptysis. Two SCPA patients did not survive to discharge. During a median follow-up of 32.5 (12.5, 87.5) months, freedom from mortality was 75%, with all three deaths occurring in the SCPA group by 4 months posthemoptysis. Recurrent hemoptysis occurred in 60% of patients.
Despite the potentially life-threatening nature of hemoptysis in patients with SV-CHD, a policy of bronchoscopic evaluation and transcatheter treatment is safe and may contribute to low mortality at mid-term follow-up in Fontan patients. Hemoptysis in SCPA patients may portend a poor prognosis. Recurrent hemoptysis is common.
描述姑息性单心室先天性心脏病(SV-CHD)患者出现危及生命的气道出血(咯血)并接受治疗后的急性和中期结果。
这是一项 2004 年至 2015 年间在一家大型先天性心脏病中心因咯血就诊的 SV-CHD 患者的病例系列研究。
12 例患者共发生 21 次咯血(58%为女性,中位数年龄为 10.5(IQR 7.2,16.4)岁)。首次咯血发生在 Fontan 完成后(n=8)、上腔静脉-肺动脉吻合术(SCPA,n=3)后和 1 例分流依赖患者。14/21(67%)初始导管插入术中同时进行支气管镜检查和导管插入术。95%的支气管镜病例均明确了气道出血的特定解剖来源,且均匀分布于所有肺段。在 30 次导管插入术中,28 次进行了经导管介入治疗,包括体肺侧支动脉(SPC)闭塞。除介入性支气管镜检查期间气道出血增加(37%)外,无操作相关并发症。中位住院时间为 9.0(3.5,14.5)天,每位患者每次咯血发作需行 1.0(1.0,2.0)次导管插入术。2 例 SCPA 患者未存活至出院。中位随访 32.5(12.5,87.5)个月期间,死亡率为 75%,所有 3 例死亡均发生在 SCPA 组,发生在咯血后 4 个月。60%的患者出现复发性咯血。
尽管 SV-CHD 患者的咯血具有潜在的致命性,但行支气管镜评估和经导管治疗的策略是安全的,可能有助于 Fontan 患者中期随访的低死亡率。SCPA 患者的咯血可能预示预后不良。复发性咯血常见。